title: New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
abstract: New gene expressed in prostate (NGEP) is a prostate-specific gene encoding either a small cytoplasmic protein (NGEP-S) or a larger polytopic membrane protein (NGEP-L). NGEP-L expression is detectable only in prostate cancer, benign prostatic hyperplasia and normal prostate. We have identified an HLA-A2 binding NGEP epitope (designated P703) which was used to generate T cell lines from several patients with localized and metastatic prostate cancer. These T cell lines were able to specifically lyse HLA-A2 and NGEP-expressing human tumor cells. NGEP-P703 tetramer binding assays demonstrated that metastatic prostate cancer patients had a higher frequency of NGEP-specific T cells when compared with healthy donors. Moreover, an increased frequency of NGEP-specific T cells was detected in the peripheral blood mononuclear cells of prostate cancer patients post-vaccination with a PSA-based vaccine, further indicating the immunogenicity of NGEP. These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer.
authors.affiliation: Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
authors.forename: Vittore
authors.initials: V
authors.lastname: Cereda
authors.forename: Diane J
authors.initials: DJ
authors.lastname: Poole
authors.forename: Claudia
authors.initials: C
authors.lastname: Palena
authors.forename: Sudipto
authors.initials: S
authors.lastname: Das
authors.forename: Tapan K
authors.initials: TK
authors.lastname: Bera
authors.forename: Cinzia
authors.initials: C
authors.lastname: Remondo
authors.forename: James L
authors.initials: JL
authors.lastname: Gulley
authors.forename: Philip M
authors.initials: PM
authors.lastname: Arlen
authors.forename: Junko
authors.initials: J
authors.lastname: Yokokawa
authors.forename: Ira
authors.initials: I
authors.lastname: Pastan
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schlom
authors.forename: Kwong Y
authors.initials: KY
authors.lastname: Tsang
mesh_terms: D000075368:Anoctamins; D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis* / Q000276:immunology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011467:Prostate / Q000378:metabolism*; D017430:Prostate-Specific Antigen / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000628:therapy; D011485:Protein Binding; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: C498181:ANO7 protein, human; D000075368:Anoctamins; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D008565:Membrane Proteins; D017430:Prostate-Specific Antigen